News
Neuroprotective Efficacy and Safety of Vinpocetine in Patients with Acute Ischemic Stroke
A meta-analysis of 4 randomized placebo-controlled studies demonstrated the benefits of vinpocetine in patients with ischemic stroke (iCMP). Administering vinpocetine within 14 days of the onset of the stroke significantly reduced the level of disability and the proportion of those who died or were dependent on others after 1 and 3 months. The results showed benefits in several other parameters and indicated very good tolerability of this drug used to increase cerebral blood flow.
Analysis of the Benefits of Combining Enalapril/Bisoprolol in Patients with Acute MI
A recently published retrospective analysis compared the outcomes achieved by administering…
New scoring system for predicting long-term survival of AML patients over 70 years and suitable for intensive chemotherapy
Based on the analysis of data from 3 large European registries (DATAML, SAL, and PETHEMA), a…
Maintenance Therapy of a Female Patient with AML After Intense Chemotherapy – Case Study
The following case study presents the case of a female patient with acute myeloid leukemia (AML)…
Efficacy and Safety of Romosozumab in Postmenopausal Women with Osteoporosis and Renal Impairment
The coexistence of osteoporosis and chronic kidney disease (CKD) increases the risk of fractures…
Previous Treatment of Osteoporosis May Affect the Efficacy of Romosozumab
A study conducted by a team of authors from several clinical sites in Japan shows that the type and…
Will 3D Printable Tissue Adhesives Replace Stitches and Clips?
3D printing technology is slowly making its way into more and more areas of healthcare. In February…
Over the Last 25 Years, Latanoprost Has Changed the Paradigm of Glaucoma Treatment
An important milestone in the treatment of glaucoma was the introduction of latanoprost with an…
New Technology Teaches Healthcare Professionals to Deliver Messages Patients Don't Want to Hear
Communication with patients and their relatives is often very challenging for doctors and nurses,…
EAHAD 2024: Fresh results of paradigm5 and 6 studies confirm safety and efficacy of N9-GP
Nonacog beta pegol (N9-GP) is a recombinant factor IX with an extended half-life. Its properties…
Popular this week
- New Platform May Accelerate Diagnosis of Alzheimer’s Disease
- Benign acute childhood myositis as a complication of influenza B and its differential diagnosis
- BENIGN DERMATOSIS OF PENIS
- Can Dogs Detect Parkinson’s Disease by Smell?
- Treatment of Tumors Using Ultrasound? The First Results of the Use of Histotripsy Look Promising